Differentiation of pathogenic Entamoeba histolytica infections from nonpathogenic infections by detection of galactose-inhibitable adherence protein antigen in sera and feces.
Differentiation of pathogenic Entamoeba histolytica infections from nonpathogenic infections by detection of galactose-inhibitable adherence protein antigen in sera and feces.
复制标题
通过检测血清和粪便中半乳糖抑制粘附蛋白抗原来区分致病性溶组织内阿米巴感染与非致病性感染。
DOI：
10.1128/jcm.31.11.2845-2850.1993
复制
发表时间：
1993
影响因子：
9.4
通讯作者：
Ravdin,JI
中科院分区：
文献类型：
--
作者：
Abd-Alla,MD;Jackson,TF;Gathiram,V;el-Hawey,AM;Ravdin,JI
我们确定了针对溶组织内阿米巴半乳糖抑制黏附蛋白(GIAP)的表位特异性单抗是否可以用于酶联免疫吸附试验(ELISA)，以检测血清和粪便中的抗原，并区分非致病酵母菌和需要治疗的潜在侵袭性致病生物。总体而言，埃及开罗57%的有症状的肠道阿米巴病患者和42%的无症状感染患者的血清中有GIAP抗原，而在未感染的对照组或有其他寄生虫感染的患者中有4%的血清中有GIAP抗原(P<；0.001)。在来自南非德班的受试者中，只有6%的未感染对照组或非致病性溶组织埃希菌感染者血清GIAP阳性，而4例无症状致病性肠道感染和75%的阿米巴肝脓肿患者血清GIAP阳性。对15份肠道阿米巴病患者粪便标本进行检测，均为粪便GIAP抗原阳性。抗原表位特异性的单抗鉴定了15名来自致病菌株粪便抗原的受试者中的8名。这8名受试者中有7名血清中有黏附蛋白抗原，而7名明显非致病性溶组织埃希氏菌感染的受试者中没有一名血清中有黏附蛋白抗原。综上所述，我们能够通过酶联免疫吸附试验直接检测血清和粪便标本中的溶组性肠杆菌黏附蛋白抗原。血清中阿米巴抗原的存在对致病性溶组织埃希氏菌感染的特异性为94%，而阿米巴抗原在无症状的肠道感染中存在。结合抗体检测，这种方法在肠道阿米巴病的诊断和治疗中应该是非常有用的。
We determined whether epitope-specific monoclonal antibodies to the galactose-inhibitable adherence protein (GIAP) of Entamoeba histolytica could be used in an enzyme-linked immunosorbent assay (ELISA) to detect antigen in serum and feces and differentiate between nonpathogenic zymodemes and the potentially invasive pathogenic organisms that require treatment. Overall, 57% of subjects from Cairo, Egypt, with symptomatic intestinal amebiasis and 42% with asymptomatic infection possessed GIAP antigen in their sera, whereas 4% of uninfected controls or subjects with other parasitic infections possessed GIAP antigen in their sera (P < 0.001). In subjects from Durban, South Africa, only 6% of uninfected controls or those with nonpathogenic E. histolytica infection were positive for GIAP in serum, whereas 3 of 4 with asymptomatic pathogenic intestinal infection and 75% with amebic liver abscess were positive for GIAP in serum. Fifteen stool samples from patients with intestinal amebiasis were available for study; all had a positive ELISA result for fecal GIAP antigen. Epitope-specific monoclonal antibodies identified 8 of 15 subjects with fecal antigen from pathogenic strains. Seven of those eight subjects had adherence protein antigen in their sera, whereas none of seven with apparent nonpathogenic E. histolytica infection had adherence protein antigen in their sera. In summary, we were able to detect E. histolytica adherence protein antigen directly in serum and fecal samples by ELISA. The presence of amebic antigen in serum demonstrated 94% specificity for pathogenic E. histolytica infection, and amebic antigen is present during asymptomatic intestinal infection. In conjunction with antibody detection, this method should be very useful in the diagnosis and management of intestinal amebiasis.